130 related articles for article (PubMed ID: 9137800)
1. Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study.
Frasci G; Comella P; Parziale A; Casaretti R; Daponte A; Gravina A; De Rosa L; Gallipoli A; Comella G
Ann Oncol; 1997 Mar; 8(3):291-3. PubMed ID: 9137800
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
3. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
Frasci G; Panza N; Comella P; Cartení G; Guida T; Nicolella GP; Natale M; Lombardi R; Apicella A; Pacilio C; Gravina A; Lapenta L; Comella G
Ann Oncol; 1999 Mar; 10(3):355-8. PubMed ID: 10355583
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
Rowinsky EK; Chaudhry V; Forastiere AA; Sartorius SE; Ettinger DS; Grochow LB; Lubejko BG; Cornblath DR; Donehower RC
J Clin Oncol; 1993 Oct; 11(10):2010-20. PubMed ID: 7692001
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
Dees EC; Rowinsky EK; Noe DA; O'Reilly S; Adjei AA; Elza-Brown K; Donehower RC
Invest New Drugs; 2003 Feb; 21(1):75-84. PubMed ID: 12795532
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
[TBL] [Abstract][Full Text] [Related]
13. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
Lokich JJ; Anderson N; Bern M; Coco F; Dow E
Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
[TBL] [Abstract][Full Text] [Related]
14. A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors.
Huber MH; Lee JS; Newman RA; Fossella FV; Wester M; Hong WK; Lippman SM
Ann Oncol; 1996 Jan; 7(1):59-63. PubMed ID: 9081393
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.
Pagani O; Sessa C; Martinelli G; Cerny T; de Jong J; Goldhirsch A; Zimatore M; Cavalli F
Ann Oncol; 1997 Jul; 8(7):655-61. PubMed ID: 9296218
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
